Register | Login
Intellectual Property Today
RFC Express - Document Management System
2013 Top Patent Firms
2013 Top Trademark Firms
Current Issue
_blank

Advertising Opportunities

Click Here

Email A Friend Back to Archived News


ImmunoCellular Therapeutics Granted Monoclonal Antibody Technology Patent


Wednesday, April 29, 2009

Los Angeles, CA -- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company, announced the issuance of a U.S. patent relating to the company’s monoclonal antibody therapeutics. Patent No. 7,498,129 entitled "Myeloma Cell and Ovarian Cancer Cell Surface Glycoproteins, Antibodies Thereto, and Uses Thereof," covers the use of IMUC’s antibodies to measure the effectiveness of the company’s proposed treatment of multiple myeloma and ovarian cancer using the company’s proprietary molecular antibodies. This builds on IMUC’s existing patent portfolio covering technologies for both the detection and the treatment of multiple types of cancer.

"This patent provides additional strength to the growing intellectual property position that we are building around our antibody technologies for the detection and the treatment of cancer," stated Manish Singh, Ph.D., president and chief executive officer of IMUC. "We are actively exploring potential partnering opportunities to enable us to bring these promising technologies through clinical testing and commercialization."

"I am very encouraged by the preclinical data that we’re observing with these antibodies, most notably their high specificity for binding to multiple myeloma and ovarian cancer, and believe that they could represent a major step forward in the treatment of certain cancers," stated Cohava Gelber, Ph.D., inventor of the antibody technology and scientific advisor to IMUC. "With approximately 22,000 new cases of ovarian cancer each year and with more than 63,000 people living with multiple myeloma, both of these cancers would greatly benefit from more effective treatment alternatives."

IMUC, through its acquisition of monoclonal antibody-related technology from Molecular Discoveries LLC, has several novel monoclonal antibodies. ICT-109, the company’s lead antibody product candidate, is a monoclonal antibody targeting small cell lung cancer (SCLC) and pancreatic cancer. This candidate is currently in pre-clinical development, and the company plans to couple it with a diagnostic kit to prescreen patients for the specific antigens that bind to ICT-109. ICT-109 has demonstrated encouraging preliminary data in pre-clinical studies and with appropriate support from a corporate partner or licensee, could be ready to enter clinical trials in 2010 for SCLC and pancreatic cancer indications.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune based therapies for the treatment of brain and other cancers. The company’s "off the shelf" therapeutic vaccine product candidate targeting cancer stem cells for multiple cancer indications is expected to enter clinical trials during the third quarter of 2009. IMUC is in pre-clinical development of a monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery using differential immunization for diagnosing and treating multiple types of cancer. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the risk that patents issued for IMUC’s monoclonal antibody product candidates may not be enforceable or may not provide commercially significant protection for these candidates; the need to confirm preliminary pre-clinical data for IMUC’s lead monoclonal antibody and other monoclonal antibody product candidates; the risks associated with pre-clinical and clinical development of molecular antibody and other product candidates; the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages; and the potential inability to secure corporate partners or licensees for development of the monoclonal antibody product candidates. Additional risks and uncertainties are described in IMUC’s most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K, IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Back to Archived News
Looking for...

  © Copyright 2013 Intellectual Property Today
Download Adobe Reader for free